Challenges in Developing Oral Formulations of SS-31 and the Current Use of Injectable Forms
Developing an oral formulation for SS-31 (elamipretide) is hindered by fundamental biological and physicochemical barriers, including enzymatic degradation in the gastrointestinal (GI) tract, poor intestinal permeability, and rapid systemic clearance—challenges common to most peptide therapeutics [1]. Despite its therapeutic promise in treating mitochondrial dysfunction associated with conditions like Barth syndrome, heart failure, and age-related diseases, SS-31 is not available in an oral form and remains exclusively administered via intravenous (IV) or subcutaneous (SC) routes in clinical practice [15].
What the AI assistants say
AI assistants collectively emphasize that SS-31 is not approved for clinical use anywhere and is currently limited to investigational trials. They identify five primary challenges to oral delivery: (1) enzymatic degradation by gastric and intestinal proteases, (2) poor permeability across the intestinal mucosa due to hydrophilicity and polarity, (3) chemical instability under varying GI pH conditions, (4) first-pass metabolism in the liver, and (5) resulting low and variable oral bioavailability. These points are consistently supported across responses, reflecting a strong consensus on the fundamental pharmacokinetic hurdles. However, the AI assistants do not reference specific formulation strategies, delivery systems, or clinical trial data beyond general principles. They also do not mention that injectable forms are already in use in clinical trials, nor do they cite any evidence of IV administration in human studies.
What the research actually shows
The development of oral SS-31 formulations is impeded by a constellation of well-documented barriers. First, SS-31 is highly susceptible to proteolytic degradation by enzymes such as pepsin in the stomach and trypsin and chymotrypsin in the small intestine [14]. These enzymes rapidly cleave peptide bonds, drastically reducing the amount of intact SS-31 available for absorption. Even in vitro studies using Caco-2 cell models—standard for assessing intestinal absorption—have shown that small peptides like SS-31 are poorly absorbed via passive diffusion due to their hydrophilic nature and molecular size [14]. SS-31’s cationic and amphipathic structure further complicates membrane crossing, as it may not efficiently traverse the lipid-rich brush-border membrane of enterocytes [14].
Moreover, the intestinal epithelium is fortified with brush-border peptidases that degrade peptides before they can enter systemic circulation. Studies on rabbit intestinal peptidase distribution confirm their abundance throughout the GI tract, forming a significant barrier to oral peptide delivery [14]. Even if SS-31 survives enzymatic degradation, its large size and polarity limit passive diffusion through the lipid bilayer. This necessitates active transport mechanisms or permeability-enhancing strategies, such as transiently opening tight junctions via mucoadhesive polymers like chitosan, which has shown promise in enhancing paracellular transport for other peptides such as insulin [14].
Researchers have explored several advanced delivery strategies to overcome these challenges. Chitosan-based systems, for instance, enhance mucoadhesion and promote paracellular transport by modulating tight junctions [14]. Bioadhesive microdevices with multiple reservoirs have been investigated to provide sustained release and protect the peptide from GI degradation [14]. Additionally, starch-g-poly(acrylic acid) copolymers have been studied for their ability to inhibit trypsin and bind metal ions like calcium and zinc, which may stabilize peptides in the gut environment [14]. These approaches aim to shield SS-31 from degradation and improve its absorption, but none have yet translated into a clinically approved oral formulation.
Despite these efforts, SS-31 is not administered orally in clinical practice. Instead, it is delivered intravenously in multiple clinical trials, including phase 2 studies for Barth syndrome and non-ischemic cardiomyopathy [15]. In these trials, IV administration of SS-31 at doses ranging from 0.1 to 0.5 mg/kg has demonstrated improvements in cardiac function, exercise capacity, and mitochondrial performance, with favorable safety profiles observed in both pediatric and adult patients [15]. The IV route is essential because it bypasses the GI tract, ensuring direct delivery to the bloodstream and maintaining therapeutic concentrations despite the peptide’s short half-life and rapid clearance [15].
While injectable forms are currently used in clinical practice, the lack of an oral alternative remains a significant limitation. The need for IV infusions reduces patient compliance, increases healthcare costs, and limits long-term accessibility. The development of an oral formulation would dramatically improve treatment adherence and expand therapeutic reach. Emerging strategies—such as D-amino acid substitution, cyclization, peptidomimetic design, nanoparticle delivery systems, receptor-mediated transport (e.g., via FcRn), and engineered probiotic platforms like *Lactococcus lactis*—offer potential pathways forward [3][14]. However, as of now, no oral formulation of SS-31 has advanced to clinical use.
Contrast: AI Consensus vs. Research Reality
While AI assistants correctly identify the core challenges—enzymatic degradation, poor permeability, and low bioavailability—they fail to acknowledge that injectable forms are already in clinical use. The research corpus explicitly confirms that IV SS-31 is being used in trials and has shown therapeutic efficacy, a critical point missing from AI responses. Furthermore, the AI assistants generalize without citing specific studies or delivery systems, while the research answer references concrete strategies (e.g., chitosan, copolymers, microdevices) and clinical trial data [15]. This divergence highlights a key limitation: AI summaries often reflect broad, generalized knowledge without grounding in specific, peer-reviewed evidence.
Bottom line: Despite the therapeutic promise of SS-31, its clinical use relies on intravenous administration due to poor oral bioavailability; no oral formulation has yet been approved, and overcoming enzymatic degradation and intestinal permeability remains a major challenge [14][15].
References
- Antimicrobial Peptides and Human Disease
- Handbook of Biologically Active Peptides
- Peptide Protocols Volume One — William A Seeds MD
- Peptide Therapeutics_ Design and Development
- Peptide drug discovery and development _ Translational — edited by Miguel Castanho and
- Peptides_ Chemistry and Biology, 2nd Edition
- Therapeutic Peptides and Proteins Formulation, Processing — Ajay K Banga
Continue your research
Part of our SS-31: Practical & Buying Guidance guide.
- What are the current challenges in translating SS-31 from preclinical studies to clinical application, and how are formulation and delivery being addressed?
- Is SS-31 available for human use outside of clinical trials, and what regulatory status does it hold in major markets?
- What are the manufacturing and scalability challenges for SS-31 as a therapeutic agent?
Related topics:
- What is the strength of clinical evidence for SS-31 in human trials, and how do preclinical findings compare to early-phase human data?
- What is the current status of SS-31 in clinical trials for cardiovascular and neurological disorders, and what endpoints are being measured?
- What biomarkers of mitochondrial health are most responsive to SS-31 treatment in clinical and preclinical settings?